LAS VEGAS — In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, discusses the phase 2 ACUITY trial investigating privosegtor for neuroprotection in patients with optic neuritis.
According to Khanani, privosegtor, also known as OCS-05 (Oculis), is “a neuroprotective candidate activating neurotrophic signaling pathways supporting neuronal and axonal survival and preservation.” Patients were treated with an intravitreal formulation of privosegtor and steroids or placebo and steroids.
{{VIDEO}}
Results showed that privosegtor